228. 閉塞性細気管支炎 Bronchiolitis obliterans Clinical trials / Disease details


臨床試験数 : 96 薬物数 : 125 - (DrugBank : 34) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 155

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01432080
(ClinicalTrials.gov)
September 20118/9/2011Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post AllotransplantDoes Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot StudyRespiratory Tract Infections;Bronchiolitis Obliterans;Cryptogenic Organizing Pneumonia;Lung Diseases, InterstitialDrug: Prednisone;Drug: Azithromycin;Drug: Montelukast;Drug: SymbicortMaisonneuve-Rosemont HospitalThe Canadian Blood and Marrow Transplant GroupTerminated18 YearsN/AAll12Phase 2Canada
2NCT01307462
(ClinicalTrials.gov)
June 20111/3/2011Targeted Therapy of Bronchiolitis Obliterans SyndromeFluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell TransplantBronchiolitis ObliteransDrug: fluticasone propionate;Drug: montelukast sodium;Drug: azithromycinStephanie LeeNational Cancer Institute (NCI)Completed6 Years99 YearsAll36Phase 2United States
3NCT01211509
(ClinicalTrials.gov)
October 201028/9/2010Montelukast in Bronchiolitis Obliterans SyndromeA Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung TransplantationBronchiolitis Obliterans;Lung Transplantation;Graft RejectionDrug: MontelukastUniversitaire Ziekenhuizen LeuvenKatholieke Universiteit LeuvenCompleted18 Years75 YearsBoth30Phase 4Belgium
4EUCTR2010-021983-14-BE
(EUCTR)
23/09/201002/09/2010A randomized placebo-controlled double blind study to treat BOS.A randomized placebo-controlled double blind study to treat BOS. -Mortality at 1 and 2 year post diagnosis of BOS-Infection rate during BOS-Evolution of pulmonary function after diagnosis of BOS
MedDRA version: 12.1;Level: LLT;Classification code 10029888;Term: Obliterative bronchiolitis
MedDRA version: 12.1;Classification code 10049202;Term: Bronchiolitis obliterans
MedDRA version: 12.1;Classification code 10068805;Term: Follicular bronchiolitis
MedDRA version: 12.1;Classification code 10019319;Term: Heart-lung transplant rejection
MedDRA version: 12.1;Classification code 10025127;Term: Lung transplant
MedDRA version: 12.1;Classification code 10051604;Term: Lung transplant rejection
MedDRA version: 12.1;Classification code 10056409;Term: Heart and lung transplant
MedDRA version: 12.1;Classification code 10016547;Term: FEV
MedDRA version: 12.1;Classification code 10016549;Term: FEV 1 abnormal
MedDRA version: 12.1;Classification code 10016550;Term: FEV 1 decreased
MedDRA version: 12.1;Classification code 10016553;Term: FEV 1 low
Trade Name: Montelukast Teva
Product Name: montelukast teva
Product Code: NA
INN or Proposed INN: MONTELUKAST SODIUM
Other descriptive name: Singulair
UZ GasthuisbergNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Belgium
5NCT00656058
(ClinicalTrials.gov)
June 17, 20089/4/2008Montelukast to Treat Bronchiolitis ObliteransMulti-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and AdultsBronchiolitis Obliterans;Chronic Graft Versus Host Disease;Leukotriene;Montelukast;Stem Cell TransplantDrug: Singulair (Montelukast Sodium)National Cancer Institute (NCI)NULLCompleted6 Years80 YearsAll25Phase 2United States